New York—Patients who were on lower-dose statins did just as well at lowering their cholesterol as those who were on moderate- to high-intensity statin medications, according to a new study presented here at Touro College Research Day. The results call into question newer recommendations that advocated for more aggressive treatment of cholesterol.
Organized by the Touro Research Collaborative, Touro College Research Day was held on Tuesday, May 3, at the Touro College of Osteopathic Medicine and the Touro College of Pharmacy campus at 230 West 125th Street in Harlem.
In 2013, the American College of Cardiology and the American Heart Association issued controversial new guidelines recommending moderate- to high-intensity doses of statins to more aggressively lower low density lipoprotein (LDL), the bad cholesterol. “It was controversial because essentially it resulted in 12.8 million more people being placed on these statin drugs,” says the study’s lead author Martha Rumore, PharmD, Associate Professor of Social, Behavioral & Administrative Pharmacy at the Touro College of Pharmacy.
She and fellow researchers wanted to compare the older ATPIII guidelines, from the National Cholesterol Education Program (NCEP), which recommend lower doses of statins, to the newer guidelines that recommend starting on moderate- to high-intensity statins.
The retrospective study included 159 men being treated by the Veterans Association. Researchers compared those who were started on low-dose statins to those started on moderate- to high-dose statins. They measured what percent reached the target goal of <100 LDL and what percent reduced their LDL by 40 percent.
The study showed that that 57 percent of those started on low statins achieved the target of <100 LDL compared to just 53 percent of those on moderate to high statins. In addition, 38 percent of those on low statins achieved both the target LDL goal and a 40-percent reduction in LDL, while 43 percent of those on moderate to high statins achieved both goals. The authors concluded that initiating patients on high-dose statins was no more effective than starting them on low-dose statins.
“The study suggests that maybe not all patients need to be on moderate- to high-intensity statins to achieve their goal,” says Rumore. “It’s uncertain whether these new guidelines are going to provide any additional benefits compared to
the previous ATPIII guidelines, though more research is needed to confirm the